Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study